Golab-Janowska Monika, Paczkowska Edyta, Machalinski Boguslaw, Meller Agnieszka, Kotlega Dariusz, Safranow Krzysztof, Wankowicz Pawel, Nowacki Przemyslaw
Department of Neurology, Pomeranian Medical University, Szczecin, Poland.
Department of General Pathology, Pomeranian Medical University, Szczecin, Poland.
Curr Neurovasc Res. 2018;15(2):120-128. doi: 10.2174/1567202615666180611120546.
Endothelial Progenitor Cells (EPCs) have been suggested to be a therapeutic option in Acute Ischemic Stroke (AIS). Statins modulate endothelial function and preserve blood flow to tissue exposed to an ischemic insult. We tested the hypothesis that statins therapy might augment circulating EPCs in patients with AIS.
Demographic data, classical vascular risk factors, treatment and National Institutes of Health Stroke Scale data were prospectively collected from 43 consecutive AIS patients (group I), comprising - 30 treated with statins (group Statin(+)) and 13 untreated (group Statin (-)). Risk factor controls (group II) included 22 subjects matched by age, gender, and traditional vascular risk factors. EPCs were measured by flow cytometry - and the populations of circulating stem cells (CD133+), early EPCs (CD133+/VEGFR2+) and ECs CD34-/CD133-/VEGFR2+ cells were analyzed.
Patients ages ranged from 54 to 92 years (mean age 75.2 ± 11.3 years). The number of CD34-/CD133-/VEGF-R2+ cells was significantly lower in group I than II (p<0.05). In group Statin(+) neurological deficit on the 1st, 3rd and 7th day was significantly lower in comparison Statin(-) (p<0.05). We observed significantly more frequent "improvement> 50% or complete recovery" and less frequent death in the statin-treated group. The number of early EPCs and ECs was significantly higher in the treated group on the day 3rd (p < 0.05).
Statins treatment is likely to have a positive effect on spontaneous CD133+/ VEGFR2+ and CD34-/CD133-/VEGFR2+ cell mobilization triggered by a stroke.
内皮祖细胞（EPCs）被认为是急性缺血性脑卒中（AIS）的一种治疗选择。他汀类药物可调节内皮功能，并维持流向遭受缺血损伤组织的血流。我们检验了他汀类药物治疗可能会增加AIS患者循环EPCs数量的假设。
前瞻性收集了43例连续的AIS患者（I组）的人口统计学数据、经典血管危险因素、治疗情况及美国国立卫生研究院卒中量表数据，其中30例接受他汀类药物治疗（他汀类药物治疗组），13例未接受治疗（非他汀类药物治疗组）。危险因素对照组（II组）包括22例年龄、性别及传统血管危险因素相匹配的受试者。通过流式细胞术检测EPCs，并分析循环干细胞（CD133+）、早期EPCs（CD133+/VEGFR2+）及内皮细胞CD34-/CD133-/VEGFR2+细胞群体。
患者年龄在54至92岁之间（平均年龄75.2±11.3岁）。I组中CD34-/CD133-/VEGF-R2+细胞数量显著低于II组（p<0.05）。在他汀类药物治疗组中，第1天、第3天和第7天的神经功能缺损明显低于非他汀类药物治疗组（p<0.05）。我们观察到他汀类药物治疗组中“改善>50%或完全恢复”更为频繁，死亡则较少见。治疗组在第3天时早期EPCs和内皮细胞数量显著更高（p<0.05）。
他汀类药物治疗可能对由中风引发的自发性CD133+/VEGFR2+和CD34-/CD133-/VEGFR2+细胞动员产生积极影响。
